Adaptive Phage Therapeutics

  • About APT
  • Contact
  • Careers
  • The Science
  • Pipeline
  • Case Studies
  • News Room
  • Patient Access
  • Clinical Studies

News Room

Latest Press Releases

  • Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical TrialJanuary 24, 2023
  • Adaptive Phage Therapeutics Appoints Edward Fang as Chief Medical OfficerOctober 25, 2022
  • Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical TrialOctober 4, 2022
  • Adaptive Phage Therapeutics Announces “The AMR RAPID™ Challenge” for the Infectious Disease Research Community: Find a Bacteria Resistant to APT’s Investigational Phage BankSeptember 7, 2022
  • Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot OsteomyelitisMay 25, 2022
  • Adaptive Phage Therapeutics Appoints Rob Casper as Vice President of Clinical OperationsApril 26, 2022
  • Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action FundApril 4, 2022
  • Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis StudyNovember 2, 2021
  • Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious DiseasesSeptember 30, 2021

See all press releases

Get to know us

Featured Stories

Company Fact sheet

Adaptive Phage Therapeutics

  • About APT
  • Contact
  • Careers
  • The Science
  • Pipeline
  • Case Studies
  • News Room
  • Patient Access
  • Clinical Studies
  • LinkedIn
  • Twitter
  • Email
  • Job Board
  • Privacy Policy